Topic:

Chutes and Ladders

Latest Headlines

Latest Headlines

UPDATED: Ackman-led hedge fund Pershing Square scores seat on Zoetis board

Under pressure from activist investor William Ackman of hedge fund Pershing Square Capital, animal health giant Zoetis said today it has named Ackman's colleague, William Doyle, to its board of directors. Doyle will serve on the board's corporate governance committee. Furthermore, Zoetis and Pershing Square have agreed to elect "an additional independent director mutually acceptable" to both companies, Zoetis said in a press release.

Amid new drug negotiations, China puts price-management vet in charge of CFDA

SINGAPORE-- A change in leadership at the China Drug and Food Administration was announced on the Communist Party website last week: Bi Jingquan, who has more than 20 years of experience in pricing and management, will take over from Zhang Yong as CFDA minister.

Viehbacher's ouster, severance raise red flags for CEO candidates

So far, Sanofi has come up empty-handed in its hunt for a CEO to replace the ousted Chris Viehbacher. And the mystery surrounding his firing may have something to do with it.

Alexion names David Hallal its next CEO

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Karolinska Development CEO leaves 3 months after taking the job

In October, Karolinska Development's board of directors was convinced Bruno Lucidi was the right person to lead the company's turnaround strategy. Now, Lucidi is out of the door, having disagreed with the board over the implementation of the plan.

Challenger says 2015 a year to send out your resume, pharma folks

Layoffs have been a common refrain for the pharma industry in recent years, but with the economy picking up, private equity flowing into the business and a bunch of great drugs coming online, layoffs were down last year and this year should be one in which hiring sucks up some of the displaced folks from years past. At least that is the contention of experts who track these matters closely.

COO Caforio named incoming BMS chief

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

BIO is preparing small biotechs for life in the social media maelstrom

Last year the campaign for Chimerix to give an experimental cancer drug to a 7-year-old gave biopharma firms another reason to be wary of the power of social media. Having seen Chimerix be engulfed by the social media maelstrom, BIO is working to equip small biotechs with the skills they will need if they find themselves in a similar situation.

Gilead's John Martin scores 'best CEO' trophy for huge stock gains

U.S. CEO watchers can't get enough of Gilead Sciences chief John Martin. After catching bouquets from Harvard Business Review and a Tuck School of Business executive rater, Martin now wins the annual "best chief executive" trophy from investment firm Morningstar.

Rooting for a French CEO at Sanofi? Take another name off your list of prospects

Another purported Sanofi CEO candidate has publicly knocked himself off the list. Takeda chief operating officer and CEO-in-waiting Christophe Weber says he's not interested in the job. That makes two top pharma execs who've rebuffed the French drugmaker.